US Drug Recall Register

FDA Drug Recalls

11,815 recalls · Class II, newest first

Risk Class IClass IIClass III
Status OngoingCompletedTerminated
Year 2026202520242023
Class II · Moderate risk Terminated

Testosterone Cypionate 100 mg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1640-2015
Class II · Moderate risk Terminated

SUPER LIPO Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1639-2015
Class II · Moderate risk Terminated

Sufentanil 50 mcg/ml + Bupivacaine 0.25 mg/ml Solution

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1638-2015
Class II · Moderate risk Terminated

Sufentanil 50 mcg/ml Solution

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1637-2015
Class II · Moderate risk Terminated

Sufentanil 45 mcg/ml + Bupivacaine 5 mg/ml Solution

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1636-2015
Class II · Moderate risk Terminated

Sodium Tetradecyl Sulfate 5% Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1635-2015
Class II · Moderate risk Terminated

Sodium Ascorbate 500 mg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1634-2015
Class II · Moderate risk Terminated

Sermorelin 300 mcg/ml + GHRP-2 300 mcg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1633-2015
Class II · Moderate risk Terminated

Sermorelin 1000mcg/GHRP6 1000/GHRP2 1000 ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1632-2015
Class II · Moderate risk Terminated

Sermorelin/GHRP6 1000/1000 mcg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1631-2015
Class II · Moderate risk Terminated

Sermorelin/GHRP2 1000/1000 mcg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1630-2015
Class II · Moderate risk Terminated

Sermorelin 1000 mcg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1629-2015
Class II · Moderate risk Terminated

Selenium 200 mcg/ml Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1628-2015
Class II · Moderate risk Terminated

Pyridoxine Hydrochloride 100 mg/ml Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1627-2015
Class II · Moderate risk Terminated

Progesterone 100 mg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1626-2015
Class II · Moderate risk Terminated

Polidocanol 5% Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1625-2015
Class II · Moderate risk Terminated

Polidocanol 1% Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1624-2015
Class II · Moderate risk Terminated

Pge 80

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1622-2015
Class II · Moderate risk Terminated

Pge 40

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1621-2015
Class II · Moderate risk Terminated

Pge 150

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1620-2015
Class II · Moderate risk Terminated

Oxytocin 100 units/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1619-2015
Class II · Moderate risk Terminated

Neomycin + Polymyxin B+ Bacitracin Ophthalmic Ointment

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1618-2015
Class II · Moderate risk Terminated

Nandrolone Decanoate 250 mg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1617-2015
Class II · Moderate risk Terminated

Nandrolone Decanoate 200 mg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1616-2015